eptinezumab
Sign in to saveAlso known as ALD403
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.
~3 min read
Encyclopedic overview
9 sectionsContents
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Names
- References
- External links
Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.
Eptinezumab was approved for medical use in the United States in February 2020, and in the European Union in January 2022.
Excerpted from Wikipedia’s “eptinezumab” article, available under the CC BY-SA 4.0 licence.
Available in 8 languages
via Wikidata sitelinks · CC0